EP1227793A1 - Formulation de cyclosporine - Google Patents

Formulation de cyclosporine

Info

Publication number
EP1227793A1
EP1227793A1 EP00971598A EP00971598A EP1227793A1 EP 1227793 A1 EP1227793 A1 EP 1227793A1 EP 00971598 A EP00971598 A EP 00971598A EP 00971598 A EP00971598 A EP 00971598A EP 1227793 A1 EP1227793 A1 EP 1227793A1
Authority
EP
European Patent Office
Prior art keywords
component
preconcentrate
composition
composition according
solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00971598A
Other languages
German (de)
English (en)
Inventor
Yusuf Khwaja Windsor Villa Hamied
Vinay G. B-38 Suryakiran Society NAYAK
Geena Malhotra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cipla Ltd
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IN1999/000062 external-priority patent/WO2001032143A1/fr
Priority claimed from GB0012816A external-priority patent/GB2362573A/en
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of EP1227793A1 publication Critical patent/EP1227793A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Definitions

  • This invention relates to improved pharmaceutical compositions for the administration of water-insoluble pharmaceutically active substances especially, but not exclusively, cyclosporin.
  • EP-A-0760237 there is described a pre-concentrate microemulsion composition
  • a pre-concentrate microemulsion composition comprising a water- insoluble pharmaceutically active material; a C 8 - C 2 o fatty acid mono-, di- or tri- glyceride from a vegetable oil or any mixture of two or more thereof; and a phospholipid and another surfactant.
  • a stable oil-in-water microemulsion can be formed by mixing the preconcentrate composition with a hydrophihc phase.
  • the microemulsion compositions of EP 0760237 are made by directly dissolving the active material in the oil phase and then dispersing the oil phase in the hydrophihc phase. This has certain advantages.
  • a pharmaceutical composition in the form of a preconcentrate mixed either with a liquid hydrophihc phase to form a stable oil-in-water microemulsion or with a solid carrier to form a stable, solid blend of carrier and preconcentrate which composition is substantially free from ethanol and comprises: a) a water-insoluble pharmaceutically active material; b) one or more propylene glycol esters of a fatty acid; c) surfactant; and either d) a hydrophihc phase, wherein component (a) has been wholly directly dissolved in component (b) and component (b) is dispersed as tiny particles in component (d); or e) a solid carrier.
  • a process for making a composition according to the invention comprises dissolving component (a) in component (b) optionally with component (c), and then mixing the resulting solution either with component (d) or with component (e), and component (c) if not included earlier.
  • the method of the invention thus comprises first forming a preconcentrate by directly dissolving component (a) in component (b), the preconcentrate also containing component (c) but being free from hydrophihc phase, and then mixing the preconcentrate with the hydrophihc phase, to form a stable oil-in water microemulsion, the composition being free from ethanol.
  • the method of the invention comprises first forming a preconcentrate by directly dissolving component (a) in component (b), the preconcentrate also containing component (c), and then mixing the preconcentrate with the solid carrier, to form a solid, table composition of preconcentrate and carrier, the composition being free from ethanol.
  • the present invention therefore encompasses two different formulations of the basic preconcentrate mixture. Both of these formulations possess the advantage of increased bioavailability of the active material.
  • the invention provides a stable oil-in-water microemulsion composition wherein components (a) to (c) above have first been formed into a preconcentrate by wholly directly dissolving component (a) in component (b) optionally in the presence of component (c) (i.e. component (c) may be added later), and then mixing the preconcentrate with a hydrophihc phase.
  • the microemulsion composition is generally liquid at room temperature and can, therefore, be advantageously provided in, for example, a soft gelatine capsule or as an oral solution such as an aqueous drink, for instance.
  • the invention provides a stable, solid formulation comprising a blend of the basic preconcentrate mixture with a solid carrier.
  • the preconcentrate mixture having increased bioavailability of the active material can, for example, be formulated into a free-flowing powder which, in turn can, for instance, be put into a hard gelatin capsule or compressed into a table.
  • component (a) is a water insoluble pharmaceutically active material.
  • the invention is particularly useful with the cyclosporins, e.g. cyclosporin A. dihydrocyclosporin C, cyclosporin D and dihydrocyclosporin D. It is also useful with other water-insoluble substances such as, for example, water-insoluble peptides, or water-insoluble antimicrobial or antineoplastic substances. Examples include desmopresin, calcitonin, insulin, lenprolide, erythropoetin, a cephalosporin, vincristine, vinblastine, taxol, etoposide or mixtures thereof.
  • component (a) is in solution in component (b).
  • Component (b) can be a propylene glycol ester of a fatty acid or a mixture of any two or more such esters.
  • the fatty acids may optionally be derived from a vegetable oil and are preferably C 8 - C 20 residues.
  • Particular preferred compounds are propylene glycol monocaprylate (Caprgol 90) and propylene glycol monolaurate (Lauroglycol 90).
  • Caprgol 90 propylene glycol monocaprylate
  • Liauroglycol 90 propylene glycol monolaurate
  • oleoyl macrogol-6 glycerides (Labrafil M 1944 CS), linoleoyl macrogol-6 glycerides (Labrafil M 2125 CS), and caprylocaproyl macrogol-8 glycerides (Labrasol) are particularly preferred compounds for use with the oils employed in the present invention.
  • Component (c) is a surfactant to provide the preconcentrate mixture and, where employed, the fully formed microemulsion with stability.
  • surfactants which can be used, but we prefer to use polyoxyl 40 hydrogenated castor oil, polyoxyethylene-sorbitan monooleate, polyoxyethylene-sorbitan monopalmitate, polyoxyethylene-sorbitan monolaurate or polyoxyethylene sorbitan monostearate.
  • the surfactant can be mixed with a phospholipid, such as lecithin.
  • a weight ratio of component (a) to surfactant of about 1 :1 to about 1 :50, but ratios outside this range can also be employed if desired.
  • a phospholipid is included in the composition, we prefer to use a weight ratio of component (a) to phospholipid of about 1 :05 to about 1 :5.0, but, again, other ratios can be used.
  • component (d) is a hydrophihc phase.
  • the preferred material is propylene glycol or diethylene glycol monoethyl ether (transcutol) but other substances can be used. Ethanol cannot be present. Water can of course also be present but it is not preferred.
  • propylene glycol component (a) remains wholly dissolved in the oil phase (component (b)).
  • Microemulsions are transparent due to the very small particle size of the dispersed phase, typically less than 200 nm. Such small droplets produce only weak scattering of visible light when compared with that from the coarse droplets (1 -10 nm) of normal emulsions.
  • An essential difference between microemulsions and emulsions is that microemulsions form spontaneously and, unlike emulsions, required little mechanical work in their formulation.
  • General reviews on microemulsions are provided by Attwood D. et al J. Colloid Interface Sci 46:249 and Kahlweit M. et al J. Colloid Interface Sci 118:436.
  • microemulsions can be formed by diluting with aqueous liquid (e.g. water, fruit juice, milk etc.) to form an oil-in-water microemulsion, e.g. for oral administration.
  • aqueous liquid e.g. water, fruit juice, milk etc.
  • the role played by bile salts in the initial step of fragmentation of fat globules, essential for fat digestion, is circumvented.
  • the rate determining factor for the absorption of drug in the vehicle is not the enzymatic metabolism of triglycerides but rests primarily in the breakdown of the fat globules into micro particles since the enzymes (lipases) act mainly at the surface of the fat globules.
  • the weight percent of hydrophilic phase is generally up to about 75%, most usually from 15 to 50%, and preferably from 35 to 50%.
  • component (e) is employed instead of component (d).
  • Preferred solid carriers include colloidal silicon dioxide and polyvinyl pyrrolidone (cross Povidone) but other suitable inert solid substances can also be used, as will be clear to those skilled in the art.
  • the solid carrier will be in the form of a dry powder.
  • the preconcentrate mixture (comprising active material, oil and surfactant) is simply blended with the solid material such that the oily preconcentrate is absorbed by the material.
  • the blended mixture is provided in the form of a free-flowing powder.
  • Such a powder can then be easily coated, for example, into a hard gelatin capsule or, alternatively, compressed into tablets, for instance.
  • the technique of absorbing an oily phase (in this case an oily preconcentrate) on to a solid phase such as colloidal silicon dioxide followed by formulation into a final dosage form is a technique well known by those skilled in the art of formulation, so further details are considered unnecessary.
  • Both the microemulsion and solid compositions can consist only of the components described, or they can contain other substances.
  • an antioxidant e.g. D- to copherol can be used.
  • Propyl gallate may be used as an alternative.
  • compositions comprising a blend of preconcentrate and solid carrier are:
  • Glyceryl Monolinoleate (Maisine 33-1) 17.25 Propylene glycol monocaprylate
  • the blended preparations were made as follows:
  • Microemulsions of the invention were made of the compositions indicated, by dissolving the cyclosporin A in the oils and then forming the oil-in- water emulsions. The procedure was:
  • the oral solution which is filled into bottles can be administered using a syringe or more preferably with the aid of a metered dose pump with a dropper actuator.
  • compositions described in Examples 4 to 8 were subjected to stability examinations under accelerated conditions of temperature and humidity.
  • the solutions were stored at RT (25°C ⁇ 2°C). Ref 40°C-80% RH and 45°C, after filling into flint glass vials.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition pharmaceutique sous la forme d'un préconcentré mélangé soit avec une phase hydrophile liquide afin de former une micro-émulsion stable huile dans eau, soit avec un support solide afin de former un mélange solide, stable, de support et de préconcentré. Cette composition comprend a) un principe, actif sur le plan pharmaceutique, insoluble dans l'eau, b) un ou plusieurs esters de propylène glycol d'acide gras, c) un agent tensio-actif, et d) une phase hydrophile, ou e) un support solide. Dans cette composition, le composant (a) a été en totalité directement dissout dans le composant (b) et le composant (b) est dispersé sous forme de fines particules dans le composant (d) ou dans le composant (e). La composition ne contient sensiblement pas d'éthanol.
EP00971598A 1999-11-02 2000-10-27 Formulation de cyclosporine Withdrawn EP1227793A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
WOPCT/IN99/00062 1999-11-02
PCT/IN1999/000062 WO2001032143A1 (fr) 1999-11-02 1999-11-02 Composition pharmaceutique pour administer des substances actives sur le plan pharmaceutique insolubles dans l'eau et procede de preparation afferent
GB0012816A GB2362573A (en) 2000-05-25 2000-05-25 Cyclosporin formulation
GB0012816 2000-05-25
PCT/GB2000/004143 WO2001032142A1 (fr) 1999-11-02 2000-10-27 Formulation de cyclosporine

Publications (1)

Publication Number Publication Date
EP1227793A1 true EP1227793A1 (fr) 2002-08-07

Family

ID=26244360

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00971598A Withdrawn EP1227793A1 (fr) 1999-11-02 2000-10-27 Formulation de cyclosporine

Country Status (3)

Country Link
EP (1) EP1227793A1 (fr)
AU (1) AU1043201A (fr)
WO (1) WO2001032142A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
GB2391471B (en) * 2002-08-02 2005-05-04 Satishchandra Punambhai Patel Pharmaceutical compositions
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
FR2873923B1 (fr) * 2004-08-05 2007-01-12 Gattefosse Holding Sa Particule solide anhydre contenant une composition lipidique liquide et composition pharmaceutique contenant lesdites particules
WO2006085217A2 (fr) * 2005-02-08 2006-08-17 Pfizer Products Inc. Adsorbes solides de medicaments hydrophobes
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US7745400B2 (en) 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
EP2066309B1 (fr) 2007-04-04 2012-08-29 Sigmoid Pharma Limited Composition pharmaceutique orale
US8686006B2 (en) * 2008-10-22 2014-04-01 Santen Pharmaceutical Co., Ltd. Pharmaceutical composition for improving intestinal absorption
CA2762179A1 (fr) 2009-05-18 2010-11-25 Sigmoid Pharma Limited Composition comprenant des gouttes d'huile
CN107582526A (zh) 2009-08-12 2018-01-16 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
AU2015341695B2 (en) 2014-11-07 2021-07-08 Sublimity Therapeutics Limited Compositions comprising cyclosporin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
KR0146671B1 (ko) * 1994-02-25 1998-08-17 김충환 사이클로스포린-함유 분말 조성물
EP0760237A1 (fr) * 1995-08-30 1997-03-05 Cipla Limited Microémulsions huile-dans-l'eau
JP2001515491A (ja) * 1997-03-12 2001-09-18 アボツト・ラボラトリーズ 親油性化合物の投与のための親油性二成分系
ID25908A (id) * 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0132142A1 *

Also Published As

Publication number Publication date
AU1043201A (en) 2001-05-14
WO2001032142A1 (fr) 2001-05-10

Similar Documents

Publication Publication Date Title
US5929030A (en) Pharmaceutical compositions
KR101759750B1 (ko) 친수성 약물의 자가 미세-유화 경구용 약제 조성물 및 이의 제조 방법
US7799340B2 (en) Pharmaceutical compositions for lipophilic drugs
JP4761093B2 (ja) オメガ−３脂肪酸油を含む医薬組成物
KR100541198B1 (ko) 마이크로에멀젼예비농축물
EP2062571B1 (fr) Composition pharmaceutique à auto-émulsion avec une biodisponibilité améliorée
US6432445B1 (en) Pharmaceutical capsules comprising a cyclosporin
JP2011105754A (ja) シクロスポリンの投与のための親水性二成分系
US8252326B2 (en) Self-microemulsifying dosage forms of low solubility active ingredients such as co-enzyme Q10
WO2001032142A1 (fr) Formulation de cyclosporine
JP2005516959A (ja) マイクロエマルション予備濃縮物
AU777740B2 (en) Pharmaceutical compositions for oral and topical administration
TWI599368B (zh) 包含含有阿拉泊韋（ａｌｉｓｐｏｒｉｖｉｒ）的醫藥組合物之口服膠囊
EP1151755B1 (fr) Compositions pharmaceutiques contenant la cyclosporine comme agent actif
JP2006509785A (ja) ビフェニルジメチルジカルボン酸の経口用マイクロエマルション組成物
GB2362573A (en) Cyclosporin formulation
WO2001032143A1 (fr) Composition pharmaceutique pour administer des substances actives sur le plan pharmaceutique insolubles dans l'eau et procede de preparation afferent
EP0431659B1 (fr) Compositions pharmaceutiques à base de tébufélone
WO2004073693A1 (fr) Capsule souple contenant une cyclosporine et son procede de fabrication
JP2005255677A (ja) シクロスポリン製剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020523

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20030806

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040216